Lobaplatin arrests cell cycle progression, induces apoptosis and alters the proteome in human cervical cancer cell Line CaSki.
Cervical cancer is one of the most common gynecologic tumors. There is an upward trend in the incidence. The objective of this research was to explore the effect of lobaplatin on cervical cancer CaSki cells proliferation, cell cycle and apoptosis and analysis of the differential expressed proteins of CaSki cells after exposed to lobaplatin. Our findings have shown that lobaplatin inhibits cell proliferations in human cervical cancer CaSki cells in dose- and time-dependent manner. Flow cytometry assay confirmed that lobaplatin affected cervical cancer cell survival by blocking cell cycle progression in S phase and G0/G1 phase and inducing apoptosis in dose- and time-dependent manner. Lobaplatin treatment reduced polypyrimidine tract-binding protein 2, ribose-phosphate pyrophosphokinase, hypothetical protein, terminal uridylyltransferase 7, ubiquitin specific protease 16 and heterogeneous nuclear ribonucleoprotein A2/B1 expression and increase zinc finger protein 91, zinc finger protein, C-X-C motif chemokine 10 precursor, stromal cell protein and laminin subunit alpha-4 expression. Some of the differentially expressed proteins may be associated with antitumor effect of lobaplatin. Lobaplatin showed a good antitumour activity in in vitro models of human cervical cancer cells. These results indicate that lobaplatin could be an effective chemotherapeutic agent in human cervical cancer treatment by inducing apoptosis, cell cycle arrest and changing many kinds of protein molecule expression level.